Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pediatr Res ; 69(2): 135-41, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21057375

RESUMO

Low-serum IGF-I levels at birth is a risk factor for the development of retinopathy of prematurity in extremely LBW infants. We tested the hypothesis that JB1 (an IGF-I analog) prevents oxygen-induced retinopathy in our rat model. Neonatal rats were exposed to 50% oxygen with brief, clustered, hypoxic (12%) episodes from birth to P14. The pups were treated with s.c. injections of 1) JB1 (1 µg/d) on P1, P2, and P3 (JB1x3); 2) JB1 (1 µg/d) on alternate days from P1 to P13 (JB1x7); or 3) equivalent volume saline. Control littermates were raised in room air (RA) with all conditions identical except for inspired O2. Groups were analyzed after hyperoxia/hypoxia (H/H) cycling at P14 or allowed to recover in RA until P21. Systemic and ocular VEGF, soluble VEGFR-1, and IGF-I; retinal vasculature; and gene profile of retinal angiogenesis were assessed. JB1x3 was more effective with associated increases in sVEGFR-1 and decreased retinal pathologies than JB1x7. We conclude that early short-term exposure to systemic JB1 treatment normalizes retinal abnormalities seen with H/H cycling, an effect that may involve sVEGFR-1.


Assuntos
Hiperóxia/complicações , Fator de Crescimento Insulin-Like I/farmacologia , Neovascularização Patológica/tratamento farmacológico , Peptídeos/farmacologia , Vasos Retinianos/efeitos dos fármacos , Retinopatia da Prematuridade/tratamento farmacológico , Animais , Animais Recém-Nascidos , Modelos Animais de Doenças , Esquema de Medicação , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Hiperóxia/sangue , Hiperóxia/fisiopatologia , Recém-Nascido , Injeções Subcutâneas , Fator de Crescimento Insulin-Like I/administração & dosagem , Fator de Crescimento Insulin-Like I/análogos & derivados , Fator de Crescimento Insulin-Like II/metabolismo , Neovascularização Patológica/sangue , Neovascularização Patológica/etiologia , Neovascularização Patológica/genética , Neovascularização Patológica/fisiopatologia , Peptídeos/administração & dosagem , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Vasos Retinianos/metabolismo , Vasos Retinianos/fisiopatologia , Retinopatia da Prematuridade/sangue , Retinopatia da Prematuridade/etiologia , Retinopatia da Prematuridade/genética , Retinopatia da Prematuridade/fisiopatologia , Fatores de Tempo , Fator A de Crescimento do Endotélio Vascular/sangue , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/sangue
2.
Am J Transl Res ; 2(3): 332-44, 2010 Jun 08.
Artigo em Inglês | MEDLINE | ID: mdl-20589171

RESUMO

We examined the hypothesis that persistent pulmonary hypertension of the newborn (PPHN) associated with ibuprofen is due to alterations in biochemical and molecular regulators of oxidative stress and NO signaling. Newborn rats breathing 50% O2 or room air from the first day of life (P1), received early IP injections of: 1) indomethacin (0.2 mg/kg) on P1 and 0.1 mg/kg on P2 and P3; 2) ibuprofen (10 mg/kg) on P1 and 5 mg/kg on P2 and P3; or 3) saline on P1, P2 and P3, then euthanized on P4; or late treatment on P4, P5 and P6, then euthanized on P7. Lung biomarkers for oxidative stress (8- epi-PGF2a), DNA damage (8-hydroxy-2'-deoxyguanosine) and pulmonary hypertension (ET-1, big ET-1, and total NO) were assessed. Despite timing of the dose and oxygen exposure, both drugs resulted in increased alveolar size. Both drugs had no beneficial effects on oxidative stress. Indomethacin treatment in O2 resulted in higher pulmonary levels of 8-epi-PGF2alpha which was associated with downregulation of most antioxidant genes with early treatment and overexpression of GPX5 and 6 with late treatment. Early and late ibuprofen treatment suppressed hyperoxia-induced NOx production and downregulated iNOS. Postponing treatment had no significant beneficial effects on biomolecular regulators of oxidative stress and NO signaling. The effect of ibuprofen on pulmonary NOx may explain in part, the transient PPHN seen in ibuprofen-treated preterm infants.

3.
Growth Horm IGF Res ; 20(1): 31-8, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19674922

RESUMO

OBJECTIVE: Indomethacin and ibuprofen are administered to preterm neonates for symptomatic patent ductus arteriosus. The drugs suppress prostaglandins (PGs) which modulate growth and secretion of various hormones. We examined the hypothesis that early postnatal indomethacin and ibuprofen influence growth and GH-IGF-I-insulin and HPA axes in neonatal rats. DESIGN: Rat pups received IP injections of saline (Sal) on P1, P2, and P3; 10mg/kg ibuprofen on P1 followed by 5mg/kg on P2 and P3; or 0.2mg/kg indomethacin on P1 followed by 0.1mg/kg on P2 and P3. Serum and hepatic GH, GHBP and IGF-I; and serum corticosterone and insulin levels were determined. RESULTS: Ibuprofen suppressed somatic growth in the sucking rats, but the effect was transient, resolving by P14. Indomethacin had an opposite, latent effect on body weight and liver to body weight ratios in weanling rats. Both indomethacin and ibuprofen had profound hormonal effects that differed in magnitude and timing. Indomethacin resulted in a sustained elevation in corticosterone levels at P21, while ibuprofen increased serum and hepatic GH levels. Both drugs suppressed GHBP in serum at P7 and P14; and liver at P4 and P7, but a rebound increase in serum GHBP was noted at P21 with Ibuprofen only. Both drugs increased serum IGF-I at P7. The effect remained sustained with indomethacin. CONCLUSIONS: These results provide evidence for an involvement of PGs in the regulation of growth as well as the GH-IGF and HPA axes. Therefore, early postnatal exposure to PG inhibitors may further exacerbate postnatal growth restriction and ability to cope with stress.


Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Inibidores de Ciclo-Oxigenase/efeitos adversos , Permeabilidade do Canal Arterial/tratamento farmacológico , Hormônio do Crescimento/antagonistas & inibidores , Ibuprofeno/efeitos adversos , Indometacina/efeitos adversos , Animais , Animais Recém-Nascidos , Anti-Inflamatórios não Esteroides/administração & dosagem , Proteínas de Transporte/antagonistas & inibidores , Proteínas de Transporte/sangue , Corticosterona/sangue , Inibidores de Ciclo-Oxigenase/administração & dosagem , Hormônio do Crescimento/sangue , Ibuprofeno/administração & dosagem , Indometacina/administração & dosagem , Insulina/sangue , Fator de Crescimento Insulin-Like I/antagonistas & inibidores , Prostaglandinas/deficiência , Ratos , Ratos Sprague-Dawley
4.
Pediatr Res ; 64(1): 50-5, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18344903

RESUMO

Oxygen fluctuation patterns in preterm infants who develop retinopathy of prematurity (ROP) are varied and poorly represented in animal models. We examined the hypothesis that clustered (CL) episodes of hypoxia during hyperoxia results in a more severe form of oxygen-induced retinopathy (OIR) than dispersed episodes. Rat pups were exposed to alternating cycles of 1) 50% O2 with three CL episodes of 12% O2 every 6 h; or 2) 50% O2 with one episode of 12% O2 every 2 h, for 7 (P7) or 14 (P14) days postnatal age. Pups were killed after hyperoxia, or placed in room air (RA) until P21. RA littermates were killed at P7, P14, and P21. Systemic and ocular vascular endothelial growth factor (VEGF), soluble VEGFR-1 (sVEGFR-1), insulin-like growth factor I (IGF-I), and growth hormone were examined. All hyperoxia-exposed retinas had evidence of neovascularization. Animals in the CL group had a more severe form of OIR at P21 evidenced by vascular tufts, leaky vessels, retinal hemorrhage, and vascular overgrowth. These characteristics were associated with low body weight; high systemic and ocular VEGF; and low systemic and high ocular sVEGFR-1 and IGF-I. These data suggest that preterm infants who experience CL fluctuations in Pao2 during supplemental O2 therapy are at a higher risk for severe ROP.


Assuntos
Hiperóxia/complicações , Hipóxia/complicações , Fator de Crescimento Insulin-Like I/metabolismo , Retina/metabolismo , Retinopatia da Prematuridade/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , Animais , Peso Corporal , Modelos Animais de Doenças , Idade Gestacional , Hormônio do Crescimento/metabolismo , Humanos , Hiperóxia/metabolismo , Hiperóxia/patologia , Hipóxia/metabolismo , Hipóxia/patologia , Recém-Nascido , Ratos , Ratos Sprague-Dawley , Retina/patologia , Neovascularização Retiniana/etiologia , Neovascularização Retiniana/metabolismo , Retinopatia da Prematuridade/etiologia , Retinopatia da Prematuridade/patologia , Índice de Gravidade de Doença , Fator A de Crescimento do Endotélio Vascular/sangue , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...